West Pharmaceutical Services (WST) Cash & Equivalents (2009 - 2026)

West Pharmaceutical Services has disclosed Cash & Equivalents across 18 years of filings, most recently posting $521.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $521.4 million, up 29.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $521.4 million (up 29.0% YoY), and the FY2025 annual result was $791.3 million, up 63.29% from the prior year.
• Cash & Equivalents came in at $521.4 million for Q1 2026 at West Pharmaceutical Services, down from $791.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $898.6 million in Q3 2023 to a low of $404.2 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $667.7 million (2022), against an average of $666.1 million.
• Across the five-year window, Cash & Equivalents plunged 45.37% in 2024 and jumped 63.29% in 2025, its largest moves.
• West Pharmaceutical Services' Cash & Equivalents stood at $894.3 million in 2022, then fell by 4.52% to $853.9 million in 2023, then slumped by 43.25% to $484.6 million in 2024, then surged by 63.29% to $791.3 million in 2025, then slumped by 34.11% to $521.4 million in 2026.
• The last three Cash & Equivalents figures came in at $521.4 million (Q1 2026), $791.3 million (Q4 2025), and $628.5 million (Q3 2025), per Business Quant data.